Biohaven Pharmaceuticals, Inc.
Clinical trials sponsored by Biohaven Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company focused on neuroscience and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Hope for ataxia: experimental drug shows promise in Late-Stage trial
Disease control CompletedThis study tested a drug called troriluzole in 141 adults with spinocerebellar ataxia, a rare disease that affects balance and coordination. Participants took either the drug or a placebo daily for 8 weeks. The main goal was to see if troriluzole could improve symptoms like walki…
Phase 2/3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
OCD drug candidate troriluzole fails to beat placebo in large trial
Symptom relief CompletedThis Phase 3 trial tested whether adding troriluzole to standard OCD medications could reduce symptoms better than a placebo. The study enrolled 589 adults with OCD who had not responded well enough to their current treatment. After 8 weeks, troriluzole did not lead to significan…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New drug troriluzole tested for OCD patients not helped by antidepressants
Symptom relief CompletedThis completed Phase 2/3 trial tested whether adding troriluzole to standard antidepressant treatment can reduce OCD symptoms. 426 adults with moderate-to-severe OCD who had not responded well enough to their current medication took either troriluzole or a placebo for 12 weeks. T…
Phase 2/3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Could this pill help when OCD meds fall short?
Symptom relief CompletedThis study tested whether adding troriluzole to standard OCD treatment works better than a placebo. It involved 456 adults with OCD who hadn't fully responded to their current medication. The main goal was to see if troriluzole could further reduce OCD symptoms and improve daily …
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC